Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.
暂无分享,去创建一个
H. Westerblad | D. S. St. Clair | L. Ferreira | J. Moylan | M. Reid | J. Bruton | Laura A. A. Gilliam
[1] J. Argilés,et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue , 2009, British Journal of Cancer.
[2] G. Schuler,et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. , 2008, Journal of molecular biology.
[3] K. Campbell,et al. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. , 2008, Journal of applied physiology.
[4] W. Dröge,et al. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. , 2008, Antioxidants & redox signaling.
[5] N. Mariappan,et al. TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. , 2007, American journal of physiology. Heart and circulatory physiology.
[6] D. Graham,et al. Effects of buthionine sulfoximine treatment on diaphragm contractility and SR Ca2+ pump function in rats. , 2007, Journal of applied physiology.
[7] A. Nudelman,et al. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity , 2007, British Journal of Cancer.
[8] N. Kearney,et al. Patterns of fatigue during a course of chemotherapy: results from a multi-centre study. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[9] D. Butterfield,et al. Adriamycin‐mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain , 2007, Journal of neurochemistry.
[10] D. Butterfield,et al. Adriamycin-induced, TNF-α-mediated central nervous system toxicity , 2006, Neurobiology of Disease.
[11] Francisco H Andrade,et al. Contractile dysfunction and altered metabolic profile of the aging rat thyroarytenoid muscle. , 2006, Journal of applied physiology.
[12] D. S. St. Clair,et al. Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection , 2006, Molecular Cancer Therapeutics.
[13] I. Tomášková,et al. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults , 2006, Leukemia & lymphoma.
[14] Jian Huang,et al. Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] P. Jacobsen,et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. , 2004, Journal of pain and symptom management.
[16] A. Bakkaloğlu,et al. Effects of pentoxifylline in Adriamycin-induced renal disease in rats , 2004, Pediatric Nephrology.
[17] A. Dinda,et al. Protection against acute adriamycin-induced cardiotoxicity by garlic: Role of endogenous antioxidants and inhibition of TNF-α expression , 2003, BMC pharmacology.
[18] G. Schuler,et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.
[19] V. Shirinsky,et al. Alterations in Myocardial Cytoskeletal and Regulatory Protein Expression Following a Single Doxorubicin Injection , 2003, Journal of cardiovascular pharmacology.
[20] G. Lamb,et al. Effects of oxidation and reduction on contractile function in skeletal muscle fibres of the rat , 2003, The Journal of physiology.
[21] H. Westerblad,et al. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. , 2002, American journal of respiratory and critical care medicine.
[22] Patricia A. Ganz,et al. Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.
[23] B. Decallonne,et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. , 2001, Methods.
[24] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[25] Yi-Ping Li,et al. Tumor necrosis factor-α and muscle wasting: a cellular perspective , 2001, Respiratory research.
[26] H. Westerblad,et al. Contractile response of skeletal muscle to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox-modulation. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] F. Clubb,et al. Cardiac-Specific Overexpression of Tumor Necrosis Factor-&agr; Causes Oxidative Stress and Contractile Dysfunction in Mouse Diaphragm , 2000, Circulation.
[28] C. Schöneich,et al. Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. , 1999, Biochemistry.
[29] P. Stone,et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study , 1999, British Journal of Cancer.
[30] P. Iaizzo,et al. Doxorubicin chemomyectomy as a treatment for cervical dystonia: Histological assessment after direct injection into the sternocleidomastoid muscle , 1998, Muscle & nerve.
[31] N. Agell,et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice , 1998, Molecular and Cellular Endocrinology.
[32] D. Allen,et al. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse , 1998, The Journal of physiology.
[33] B. Coiffier,et al. ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS , 1996, British journal of haematology.
[34] C. Garcı́a-Martı́nez,et al. Acute treatment with tumour necrosis factor-α induces changes in protein metabolism in rat skeletal muscle , 1993, Molecular and Cellular Biochemistry.
[35] S. Piscitelli,et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.
[36] E. Voest,et al. Doxorubicin interacts directly with skinned single skeletal muscle fibres. , 1992, European journal of pharmacology.
[37] M. Siimes,et al. Skeletal muscle wasting and protein–energy malnutrition in children with newly diagnosed acute leukemia , 1990, Cancer.
[38] Aquilur Rahman,et al. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. , 1989, American journal of obstetrics and gynecology.
[39] H. Westerblad,et al. The temperature dependence of isometric contractions of single, intact fibres dissected from a mouse foot muscle. , 1987, The Journal of physiology.
[40] F. Zorzato,et al. Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. A study on isolated sarcoplasmic reticulum and chemically skinned fibers. , 1985, The Journal of biological chemistry.
[41] R. Tsien,et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.
[42] J. Doroshow,et al. Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. , 1985, The American journal of pathology.
[43] E J Freireich,et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.
[44] L. Goodman,et al. THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .
[45] D. Allen,et al. Skeletal muscle fatigue: cellular mechanisms. , 2008, Physiological reviews.
[46] D. Butterfield,et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. , 2006, Neurobiology of disease.
[47] P. Johansen. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse , 2004, Cancer Chemotherapy and Pharmacology.
[48] Y. J. Kang,et al. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. , 2002, Chemical research in toxicology.
[49] C. Angelini,et al. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents , 2000, Cancer Chemotherapy and Pharmacology.
[50] A. Scialli. Goodman and Gilman's the pharmacologic basis of therapeutics , 1991 .
[51] S. Ellenberg,et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. Close. Dynamic properties of mammalian skeletal muscles. , 1972, Physiological reviews.